Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Efficacy & Safety of Recombinant Human Erythropoietin -Alpha, (rHu-EPO-Alpha) in Patients With Anemia of Chronic Renal Failure.

NCT00399269 is registered in ClinicalTrials.gov with Cadila Pharnmaceuticals as lead sponsor.

NCT NCT00399269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00399269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Efficacy & Safety of Recombinant Human Erythropoietin -Alpha, (rHu-EPO-Alpha) in Patients With Anemia of Chronic Renal Failure.
Lead sponsor
Cadila Pharnmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2006
Completion date
June 30, 2007
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia